Home › Funds › Tejara Capital Ltd › MREO
Tejara Capital Ltd position in MREO
MEREO BIOPHARMA GROUP PLC · Health Care
Tejara Capital Ltd reported holding 2,014,508 shares of MREO (MEREO BIOPHARMA GROUP PLC) in its Q3 2026 13F filing — a position valued at US$810K, representing 0.40% of its reported portfolio and ranking #42 among its reported holdings. Tejara Capital Ltd has disclosed MREO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Tejara Capital Ltd's MREO position evolved
Tejara Capital Ltd first disclosed a stake in MREO in Q3 2023 at 3,215,001 shares (US$4.1M). The position peaked in Q3 2024 at 2,829,990 shares, worth US$11.6M. Across 13 filings, Tejara Capital Ltd increased the stake 5 time(s), trimmed it 6 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 2,014,508 shares valued at US$810K — a reduction of -23,012 shares quarter over quarter.. Notable position changes include a 33% trim in Q1 2024 (shares rose 9% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 3.22M | $4.15M | New |
| Q4 2023 | 3.71M | $8.58M | Add |
| Q1 2024 | 2.47M | $8.15M | Reduce |
| Q2 2024 | 2.62M | $9.42M | Add |
| Q3 2024 | 2.83M | $11.63M | Add |
| Q4 2024 | 2.32M | $8.11M | Reduce |
| Q1 2025 | 2.52M | $5.67M | Add |
| Q2 2025 | 2.43M | $6.59M | Reduce |
| Q3 2025 | 1.91M | $3.93M | Reduce |
| Q4 2025 | 2.16M | $899.94K | Add |
| Q1 2026 | 2.04M | $672.38K | Reduce |
| Q2 2026 | 2.04M | $647.32K | Hold |
| Q3 2026 | 2.01M | $809.83K | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MREO and 13F data
MREO (MEREO BIOPHARMA GROUP PLC) is a Health Care company. 5 other funds we track also report a position in MREO — the largest reported positions include Defilade Capital Management, L.P. (US$2.4M), Newtyn Management, LLC (US$953K). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MREO
- Defilade Capital Management, L.P. 7.56M sh · $2.40M · Q2 2026
- Newtyn Management, LLC 3.00M sh · $953.10K · Q2 2026
More on Tejara Capital Ltd
FAQ
How long has Tejara Capital Ltd held MREO?
Tejara Capital Ltd has disclosed MREO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Tejara Capital Ltd's current position in MREO?
As of Q3 2026, Tejara Capital Ltd holds 2.01M shares of MREO (MEREO BIOPHARMA GROUP PLC), valued at $809.83K, representing 0.40% of its reported portfolio and ranking #42.
Has Tejara Capital Ltd been buying or selling MREO?
In the latest 13F filing (Q3 2026), Tejara Capital Ltd reduced its position in MREO. The position peaked in Q3 2024 at 2.83M shares.
Which other funds hold MREO?
Other major institutional holders of MREO include Defilade Capital Management, L.P., Newtyn Management, LLC, among 5 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.